SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 1, 2000, Pages 281-288

  Underwood, David C ^a,b   Osborn, Ruth R ^a   Kotzer, Charles J ^a   Adams, Jerry L ^a   Lee, John C ^a   Webb, Edward F ^a   Carpenter, Donald C ^a   Bochnowicz, Steven ^a   Thomas, Heath C ^a   Hay, Douglas W P ^a   Griswold, Don E ^a  

^a SmithKline Beecham Pharmaceutical ^*  (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASTHMA; CELL INFILTRATION; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENCY; GUINEA PIG; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION;

ADMINISTRATION, INHALATION; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOCONSTRICTION; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CYTOKINES; ENZYME INHIBITORS; EOSINOPHILIA; GUINEA PIGS; HUMANS; IMIDAZOLES; LEUKOTRIENE D4; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHAGOCYTOSIS; PLETHYSMOGRAPHY, WHOLE BODY; PYRIMIDINES; RESPIRATORY SYSTEM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18544406054     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Aaes H, Griswold DE, Skak-Nielsen T, Hansen JR, Jensen L, Bramm E and Binderup L (1999) Topical antiinflammatory activites of HEP689 in 3 murine models of dermatitis. 4th World Congress on Inflammation Paris, France. Mediators Inflamm 8:S117.
2. Anderson GP (1996) Resolution of chronic inflammation by therapeutic induction of apoptosis. Trends Pharmacol Sci 17:438-442.
3. Barnes PJ (1999) New therapies for chronic obstructive pulmonary disease. Thorax 53:137-147.
4. Barnes PJ, Chung KF and Page CP (1988) Inflammatory mediators and asthma. Pharmacol Rev 40:49-84.
5. Barnes PJ, Chung KF and Page CP (1998) Inflammatory mediators of asthma: An update. Pharmacol Rev 50:515-596.
6. Bracke M, Coffer PJ, Lammers JW and Koenderman L (1998) Analysis of signal transduction pathways regulating cytokine-mediated Fc receptor activation on human eosinophils. J Immunol 161:6768-6774.
7. Giembycz MA and Lindsay MA (1999) Pharmacology of the eosinophil. Pharmacol Rev 51:213-339.
8. Griswold DE and Young PR (1996) Pharmacology of cytokine suppressive anti-inflammatory drug binding protein (CSBP), a novel stress-induced kinase. Pharmacol Commun 7:323-329.
9. Hashimoto S, Gon Y, Asai Y, Machino T, Jibiki I, Takeshita I, Anazawa H and Hone T (1999) p38 MAP kinase regulates RANTES production by TNF-alpha-stimulated human pulmonary vascular endothelial cells. Allergy 54:1168-1172.
10. Kankaanranta H, De Souza PM, Barnes PJ, Salmon M, Giembycz MA and Lindsay MA (1999) SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constituitive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 290:621-628.
11. Lee JC, Kassis S, Kumar S, Badger A and Adams JL (1999) p38 Mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials. Pharmacol Ther 82:389-397.
12. Luna LG (1968) Luna's method for erythrocytes and eosinophil granules, in Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. (Luna LG ed) pp 111-112, McGraw-Hill Book Company, New York.
13. Marshall LA, Hansbury MJ, Bolognese BJ, Gum RJ, Young PR and Mayer RJ (1998) Inhibitors of the p38 mitogen-activated kinase modulate IL-4 induction of low affinity IgE receptor (CD23) in human monocytes. J Immunol 161:6005-6013.
14. Olivera DL, Esser KM, Lee JC, Greig RG and Badger AM (1992) Benefical effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock. Circ Shock 37:301-306.
15. Selig W and Chapman R (1999) Animal models of asthma, in In Vivo Models of Inflammation (Morgan DW and Marshal LA eds) pp 111-135, Birkhauser, Basel.
16. Stern M, Meagher L, Savill J and Haslett C (1992) Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 148:3543-3549.
17. Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttman MA, Hay DWP, Gorycki PD, Christensen SB and Torphy TJ (1998a) Anti-asthmatic activity of the second generation phosphodiesterase 4 inhibitor, SB 207499 (Ariflo), in the guinea pig. J Pharmacol Exp Ther 287:988-995.
18. Underwood DC, Osborn RR, Bochnowicz S, Christensen SB, Torphy TJ and Hay DWP (1998b) The second generation phosphodiesterase (PDE) 4 inhibitor, SB 207499, inhibits antigen-induced bronchoconstriction and eosinophilia and LPS-induced airway neutrophilia and edema in the guinea pig. World Asthma Meeting, Barcelona, Spain.
19. 4 administration in the guinea pig. Am J Resp Crit Care Med 154:850-857.
20. Walsh GM (1997) Mechanisms of human eosinophil survival and apoptosis. Clin Exp Allergy 27:482-487.
21. Webb EF, Tzimas MN, Newsholme S and Griswold DE (1998) Intralesional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor a and interleukin-4. J Invest Dermatol 111:86-92.
22. Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y and Kasahara T (1991) Analysis of the survival of mature human eosinophils: Interleukin-5 prevents apoptosis in mature human eosinophils. Blood 78:2542-2547.